NuSep tries NxGen
Thursday, 02 October, 2008
Bioseparations company NuSep [ASX: NSP] has reached a binding agreement to acquire NxGen Pharmaceuticals for $25 million.
Pending shareholder approval, NuSep will acquire all of NxGen in exchange for 294 million NuSep shares valued at 8.5c each.
This represents 87.5 per cent of NuSep's expanded capital and 10 times NxGen's net profit forecast for this financial year.
NxGen is a custom pharmaceuticals manufacturer and formulator, with products including an erectile dysfunction nasal spray it makes for a medical clinic.
A scientist, a cooler and a long-haul flight in the fight against MND
Early in January 2026, neuroscientist Dr Rachael Dunlop boarded a flight from Sydney to the US...
Mini lung organoids could help test new treatments
Scientists have developed a simple method for automated the manufacturing of lung organoids...
Clogged 'drains' in the brain an early sign of Alzheimer’s
'Drains' in the brain, responsible for clearing toxic waste in the organ, tend to get...
